Price-to-Projected Revenue Ratio: Amarin (AMRN)

Official company branding of Amarin (AMRN)

How do global partnerships for the promotion of Vascepa impact the capitalization of Amarin Corporation plc (AMRN)? The expected P/S valuation provides the answer, with the current level sitting around 1.40. Business growth relies on attracting top marketers through a bonus system. However, the market image is recovering after the loss of some patents, although the therapeutic value of the drugs remains high.

AMRN Amarin: Forward Price to Sales in the range 07/04/2022 - 11/16/2026

AMRN (amarincorp.com): analytical breakdowns and indicator data

- current price and projected stock value:
- company stock exchange capitalization indicators:
Summary company analysis:Amarin Corporation AMRN
Original product of Amarin Corporation plc

The lack of alternatives to the EPA drug for reducing cardiovascular risks ensures steady market demand for Amarin Corporation plc (AMRN), which is reflected in the scale of its operations. The current level of 1.40 on the company's expected P/S chart compares market value with projected revenue, allowing investors to filter out short-term volatility and assess the real value of the business relative to its future cash flows.